Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash & Equivalents: 2017-2024

Historic Cash & Equivalents for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to $264.5 million.

  • Crinetics Pharmaceuticals' Cash & Equivalents fell 65.05% to $110.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.9 million, marking a year-over-year decrease of 65.05%. This contributed to the annual value of $264.5 million for FY2024, which is 370.75% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Cash & Equivalents of $264.5 million as of FY2024, which was up 370.75% from $56.2 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Cash & Equivalents ranged from a high of $264.5 million in FY2024 and a low of $34.0 million during FY2022.
  • Moreover, its 3-year median value for Cash & Equivalents was $56.2 million (2023), whereas its average is $118.2 million.
  • In the last 5 years, Crinetics Pharmaceuticals' Cash & Equivalents plummeted by 83.11% in 2022 and then soared by 370.75% in 2024.
  • Yearly analysis of 5 years shows Crinetics Pharmaceuticals' Cash & Equivalents stood at $93.1 million in 2020, then skyrocketed by 116.14% to $201.2 million in 2021, then slumped by 83.11% to $34.0 million in 2022, then surged by 65.42% to $56.2 million in 2023, then skyrocketed by 370.75% to $264.5 million in 2024.